CLINICAL_TRIALS
trial_result
· 2022-10-21
Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH [Phase 3]
Summary
Phase 3 trial evaluating pegcetacoplan for paroxysmal nocturnal hemoglobinuria has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED | Results posted: 2022-10-21